Trametinib’s functional indications and targets have been announced

Trametinib (Trametinib) is a small molecule tyrosine kinase inhibitor. Its main function is to treat advanced melanoma with BRAF V600E or V600K mutations. Trametinib can also be used in combination with other drugs to treat certain types of cancer, such as non-small cell lung cancer and thyroid cancer. It exerts anti-cancer effects by inhibiting the MEK signaling pathway and affecting cell proliferation and apoptosis processes.

The main target of Trametinib isMEK1/2 protein kinase, which plays a key role in cell signaling pathways and can activate multiple downstream signaling pathways, including the ERK1/2 pathway, thereby promoting cell proliferation, differentiation and survival. By inhibiting MEK1/2 activity, trametinib can prevent the growth and spread of tumor cells and induce their apoptosis.

It should be noted that trametinib can only be used for patients carryingBRAF V600E or V600K mutations, and may be ineffective or even harmful for other types of cancer. In addition, trametinib also has some side effects, such as rash, fatigue, nausea, etc., so it needs to be used correctly under the guidance of a doctor.

The original drug of Trametinib has been launched in China and is included in the scope of medical insurance. Only patients who meet the indications can choose to reimburse. The price of 2 mg*30 tablets is more than RMB 10,000. The original drug of Trametinib sold overseas is priced at more than RMB 7,000 (the price may fluctuate due to the exchange rate). There are also generic trametinib drugs produced in other countries overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 2mg*30 tablets produced by a Laos pharmaceutical factory is more than 2,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.